Recently, " Biomedicine and Pharmacotherapy " ( Biomedicine and Pharmacotherapy ) published an online study on the treatment of drug-resistant tuberculosis by the Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences
Biomedicine and Pharmacotherapy Tuberculosis, commonly known as tuberculosis, is a fatal disease caused by Mycobacterium tuberculosis, and pulmonary tuberculosis is the most common
At present, the only preventive tuberculosis vaccine used clinically is Bacillus Calmette-Guerin (BCG), which is an attenuated Mycobacterium bovis, very similar to Mycobacterium tuberculosis infected by humans, and the sequence identity of the genome exceeds 99%
So, can BCG be used in the adjuvant treatment of tuberculosis? Zhang Tianyu told China Science Daily that this may not work in theory, because almost all TB drugs are effective on BCG, and BCG may have been killed by anti-TB drugs before it can work
Therefore, the researchers proposed the preparation of selective drug-resistant BCG, that is, to give the prepared BCG resistance to the drugs selected for the treatment of tuberculosis
"We selected two proteins, Ag85B and Rv2608, which have high levels of expression in the active and dormant states, respectively, and they have been reported to have good immune protection effects
Subsequently, the researchers integrated these two genes into the prepared genome of drug-resistant wild-type BCG, and obtained a new recombinant drug-resistant BCG (RdrBCG-I) in which these two exogenous genes can be expressed very stably in vivo and in vitro.
Animal experiments show that both RdrBCG-I and wild BCG show strong safety in mice with severe immunodeficiency
In addition, studies have also confirmed that adding ordinary BCG to existing therapies has almost the same effect as not adding them, and cannot be used for adjuvant therapy
"The biomedical community has been developing therapeutic vaccines against tuberculosis, especially drug-resistant tuberculosis, but their effects have not been convincing
It is reported that this research has received funding support from the National Science and Technology Major Project, the Major New Drug Creation Project, the Chinese Academy of Sciences project, and the Guangzhou Health and Medical Collaborative Innovation Major Project
Chinese Academy of Sciences Related paper information: https://doi.
https://doi.
org/10.
1016/j.
biopha.
2021.
112047
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
